Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study

Lung Cancer

Volumn 62, Issue 1, 2008, Pages 62-71

  Blanco, Remei ^a   Solé, Josep ^b   Montesinos, Jesús ^c   Mesía, Carlos ^b   Algara, Manuel ^d   Terrassa, Josefa ^e   Gay, Monserrat ^f   Domenech, Monserrat ^g   Bastus, Romá ^h   Bover, Isabel ⁱ   Nogué, Miquel ^f   Vadell, Catalina ^j  

^a Oncology Service   (Spain)

^b HOSPITAL DURAN I REYNALS   (Spain)

^c Oncology Units   (Spain)

^d HOSPITAL DE L ESPERANÇA   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL GENERAL DE VIC   (Spain)

^g Centre Hospitalari Manresa   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ HOSPITAL SON LLÀTZER   (Spain)

^j HOSPITAL DE MANACOR   (Spain)

more..

Author keywords

Concurrent chemoradiotherapy; Gemcitabine; Locally advanced; Non small cell lung cancer; Phase II; Toxicity

Indexed keywords

CISPLATIN; GEMCITABINE;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION; INOPERABLE CANCER; KIDNEY FUNCTION; LIVER FUNCTION; LUNG EMBOLISM; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIATION DERMATITIS; RADIATION DOSE; RADIATION PNEUMONIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUBERCULOSIS; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY;

EID: 52549124954     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.02.024     Document Type: Article

References (37)

1. Grunenwald D.H. Surgery for locally advanced non small cell lung cancer. Semin Surg Oncol 21 (2003) 85-90
2. Naruke T. Surgery in locally advanced non-small cell lung cancer. Lung Cancer 42 Suppl. 2 (2003) S11-S15 [36 ref.]
3. Curran W., Scott C., Langer C., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non small cell lung cancer: Radiation Therapy Oncology Group 9410. Proc Am Soc Clin Oncol 22 (2003) 621 (abstract 2499)
4. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with misogynic, intestine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
5. Zatloukal P., Petruzelka L., Zemanova M., Havel L., Janku F., Judas L., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
6. Vokes E.E., Herndon II J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20 (2002) 4191-4198
7. Gandara D.R., Chansky K., Albain K.S., Leigh B.R., Gaspar L.E., Lara Jr. P.N., et al., Southwest Oncology Group. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
8. Fossella F.V., Zinner R.G., Komaki R., Lu R., Lee J.S., Glisson B.S., et al. Gemcitabine with concurrent chest radiation followed by consolidation gemcitabine plus cisplatin: a phase I trial for patients with stage III nonsmall cell lung cancer (NSCLC). Eur J Cancer 37 Suppl. 6 (2001) S53-S54
9. Gregor A., Price A., van der Leest A.H.D., Scalliet P., Wets M., Jungnelius U., et al. Phase I study of gemcitabine and radiotherapy in stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 18 (1999) 1953a
10. Trodella L., Granone P., Valente S., Turriziani A., Macis G., Corbo G.M., et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable nonsmall-cell lung cancer. J Clin Oncol 20 3 (2002) 804-810
11. Van Putten J.W.G., Price A., van der Leest A.H.D., Gregor A., Little F.A., and Groen H.J.M. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9 (2003) 2472-2477
12. Goor C., Scalliet P., Van Meerbeek J., et al. A phase II study combining gemcitabine and radiotherapy in stage III NSCLC. Proc 21st ESMO Ann Oncol 7 Suppl. 5 (1996) 101a
13. Salinas J., Serna A., de la Fuente I., de las Heras M., García R., and Fernández J. Gemcitabina como radiosensibilizante en el carcinoma no microcítico de pulmón estadio III. Estudio fase I-II en pacientes con quimioterapia neoadyuvante. Rev Oncol 3 Suppl. 1 (2001) 163
14. Zajusz A., Zielonka I., Sygula D., Plewicki G., Nowicka E., Behrendt K., et al. Concurrent thoracic radiotherapy and weekly gemcitabine in an advanced non-small cell lung cancer. Radiother Oncol 56 Suppl. 1 (2000) S66
15. Athanasiou E., Cyrgias G., Boinis K., Samantas E., Christodoulidou M., Tamvaki F., et al. Concurrent chemoradiotherapy with gemcitabine for locally advanced non-small cell lung cancer: preliminary results of a phase II study. Proc 23rd ESMO Ann Oncol 9 (1998) 468a
16. Fields M.T., Eisbruch A., Normolle D., Orfali A., Davis M.A., Pu A.T., et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 47 (2000) 785-791
17. Blackstock A.W., Case L.D., Richards F., White D., Petty M., Scarantino C., et al. Twice-weekly gemcitabine and concurrent thoracic radiotherapy. A phase I/II study in patients with advanced non-small cell lung cancer (NSCLC). Proc 41st ASTRO Int J Radiat Oncol Bio Phys 45 Suppl. 3 (1999) 242.183a
18. Armstrong J.G. Target volume definition for three-dimensional conformal radiation therapy of lung cancer. Br J Radiol 71 (1998) 587-594
19. ICRU. International Commission of Radiation Units and Measurements. Report 50 (1993) and Report 62 (1999).
20. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Blackstock A.W., Lesser G.J., Fletcher-Steede J., Case L.D., Tucker R.W., Russo S.M., et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 1281-1289
22. Wei X., Liu H.H., Tucker S.L., Liao Z., Hu C., Mohan R., et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 100-107
23. Robnett T.J., Machtay M., Vines E.F., McKenna M.G., Algazy K.M., and McKenna W.G. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48 (2000) 89-94
24. Rancati T., Ceresoli G.L., Gagliardi G., Schipani S., and Cattaneo G.M. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 67 (2003) 275-283
25. Inoue A., Kunitoh H., Sekine I., Sumi M., Tokuuye K., and Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 49 (2001) 649-655
26. Hara R., Itami J., Komiyama T., Katoh D., and Kondo T. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 125 (2004) 340-344
27. Yamada M., Kudoh S., Hirata K., Nakajima T., and Yoshikawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 34 (1998) 71-75
28. Yorke E.D., Jackson A., Rosenzweig K.E., Merrick S.A., Gabrys D., Venkatraman E.S., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in nonsmall-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54 (2002) 329-339
29. Kwa S.L.S., Lebesque J.V., Theuws J.C., Marks L.B., Munley M.T., Bentel G., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42 (1998) 1-9
30. Hernando M.L., Marks L.B., Bentel G.C., Zhou S.M., Hollis D., Das S.K., et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 650-659
31. Makimoto T., Tsuchiya S., Hayakawa K., Saitoh R., and Mori M. Risk factors for severe radiation pneumonitis in lung cancer. Jpn J Clin Oncol 29 (1999) 192-197
32. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
33. Tsujino K., Hirota S., Endo M., Obayashi K., Kotani Y., Satouchi M., et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55 (2003) 110-115
34. Werner-Wasik M., Xiao Y., Pequignot E., Curran W.J., and Hauck W. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume-a serial CT scan-based study. Int J Radiat Oncol Biol Phys 51 (2001) 56-61
35. Lever A.M., Henderson D., Ellis D.A., Corris P.A., and Gilmartin J.J. Radiation fibrosis mimicking local recurrence in small cell carcinoma of the bronchus. Br J Radiol 57 (1984) 178-180
36. Hicks R.J., Kalff V., Mac Manus M.P., Ware R.E., McKenzie A.F., Matthews J.P., et al. The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 42 (2001) 1605-1613
37. Mac Manus M.P., Hicks R.J., Matthews J.P., McKenzie A., Rischin D., Salminen E.K., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 (2003) 1285-1292